The institute

"I hope that in a short time, we will be able to see a great interdisciplinary center, devoted to fundamental and applied research, tightly integrated into the university and healthcare tissue of this city, fully focused to the problems of the ill citizen."

L. Donato, 1969

  schema-IFC-engl

 

From its first realization as a Laboratory in 1967, IFC, by adopting the name "Clinical Physiology", anticipated the cultural and ethical conception of what is now evidence-based medicine. The experimental research integrated into the clinic, always with the attention paid to the patient’s expectations, has realized the basic idea to add the concept of measurement - so far confined to physiological research - to medical practice. For this purpose, from the very beginning, biomedical knowledge grows and proceeds with the support of technological innovation and the results of epidemiological studies.

The IFC has a staff of over 500 "research actors", including 129 confirmed researchers and technologists (with different training and scientific culture, including medicine, biology, chemistry, bioengineering, physics, statistics, math and computer science ...) mainly in Pisa headquarters, but also in the other sites of Milan, Lecce, Rome, Siena, Massa and Reggio Calabria.

The intense collaboration of IFC researchers with the most important institutions in the world has allowed them to reach levels of excellence, together with the opportunity to be coordinators or partners in many international projects.

"Customized Assistance" is the new keyword for IFC research, which is realized through:

- health promotion and quality of life;

- monitoring and control of weaker patients and citizens;

- optimization of therapeutic interventions, together with the reduction of hospitalization times;

- modeling at various levels specific to the patient, with appropriate systems support for simulation and decision;

- more attention to patients as well as to healthcare professionals;

- new frontiers in multimodal imaging and the use of new biomaterials;

- the careful risk / benefit evaluation of the diagnostic approach used, and its suitability, with the goal of improving diagnostic and therapeutic procedures.